A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma

dc.contributor.authorBolcaen, Julie
dc.contributor.authorKleynhans, Janke
dc.contributor.authorNair, Shankari
dc.contributor.authorVerhoeven, Jeroen
dc.contributor.authorGoethals, Ingeborg
dc.contributor.authorSathekge, Mike Machaba
dc.contributor.authorVandevoorde, Charlot
dc.contributor.authorEbenhan, Thomas
dc.contributor.emailthomas.ebenhan@up.ac.zaen_US
dc.date.accessioned2022-09-21T05:04:47Z
dc.date.available2022-09-21T05:04:47Z
dc.date.issued2021-07-06
dc.description.abstractDespite numerous clinical trials and pre-clinical developments, the treatment of glioblastoma (GB) remains a challenge. The current survival rate of GB averages one year, even with an optimal standard of care. However, the future promises efficient patient-tailored treatments, including targeted radionuclide therapy (TRT). Advances in radiopharmaceutical development have unlocked the possibility to assess disease at the molecular level allowing individual diagnosis. This leads to the possibility of choosing a tailored, targeted approach for therapeutic modalities. Therapeutic modalities based on radiopharmaceuticals are an exciting development with great potential to promote a personalised approach to medicine. However, an effective targeted radionuclide therapy (TRT) for the treatment of GB entails caveats and requisites. This review provides an overview of existing nuclear imaging and TRT strategies for GB. A critical discussion of the optimal characteristics for new GB targeting therapeutic radiopharmaceuticals and clinical indications are provided. Considerations for target selection are discussed, i.e. specific presence of the target, expression level and pharmacological access to the target, with particular attention to blood-brain barrier crossing. An overview of the most promising radionuclides is given along with a validation of the relevant radiopharmaceuticals and theranostic agents (based on small molecules, peptides and monoclonal antibodies). Moreover, toxicity issues and safety pharmacology aspects will be presented, both in general and for the brain in particular.en_US
dc.description.departmentNuclear Medicineen_US
dc.description.librariandm2022en_US
dc.description.urihttp://www.thno.orgen_US
dc.identifier.citationBolcaen, J., Kleynhans, J., Nair, S., Verhoeven, J., Goethals, I., Sathekge, M., Vandevoorde, C. & Ebenhan, T. A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma. Theranostics. 2021 Jul 6;11(16):7911-7947. doi: 10.7150/thno.56639.en_US
dc.identifier.issn1838-7640 (online)
dc.identifier.other10.7150/thno.56639
dc.identifier.urihttps://repository.up.ac.za/handle/2263/87236
dc.language.isoenen_US
dc.publisherIvyspring International Publisheren_US
dc.rights© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License.en_US
dc.subjectRadiochemistryen_US
dc.subjectGioblastomaen_US
dc.subjectTheranosticsen_US
dc.subjectPET SPECT imagingen_US
dc.subjectTargeted radionuclide therapy (TRT)en_US
dc.subjectSingle photon emission computed tomography (SPECT)en_US
dc.subjectPositron emission tomography (PET)en_US
dc.titleA perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastomaen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Bolcaen_Perspective_2021.pdf
Size:
3.36 MB
Format:
Adobe Portable Document Format
Description:
Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.75 KB
Format:
Item-specific license agreed upon to submission
Description: